Keywords: Takeda, Nine months fiscal 2011 results, Nycomed
Costs take toll on earnings from Japan’s Takeda
Article | 01 February 2012
Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), yesterday released consolidated results for the nine months from April 1 to December 31, 2011, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
